EBV and Disease: New Perspectives in the Post COVID-19 Era
A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Human Virology and Viral Diseases".
Deadline for manuscript submissions: 30 April 2025 | Viewed by 163
Special Issue Editors
2. Department of Laboratory Medicine, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510630, China
Interests: interaction between EBV and host cells, especially the impact of reactivation of EBV on the development; diagnosis; treatment and prognosis of nasopharyngeal carcinoma
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Epstein–Barr virus (EBV), a ubiquitous human herpesvirus, has long been implicated in a spectrum of diseases ranging from infectious mononucleosis to malignancies such as Burkitt’s lymphoma and nasopharyngeal carcinoma. While our understanding of EBV’s pathogenesis has advanced significantly, the precise mechanisms underlying its disease-associated complications remain complex and elusive.
The unprecedented global impact of the COVID-19 pandemic has ushered in a new era of viral research and epidemiological investigation. As the world grapples with the long-term consequences of this pandemic, emerging evidence suggests a potential interplay between SARS-CoV-2 and EBV, with implications for the occurrence, progression, and clinical manifestations of EBV-related diseases.
This Special Issue aims to provide a comprehensive overview of the latest research on EBV and its associated pathologies in the context of the COVID-19 pandemic. We invite contributions that delve into the following areas:
- EBV reactivation and immune dysregulation following SARS-CoV-2 infection: Exploration of the mechanisms by which COVID-19 may trigger EBV reactivation and contribute to immune dysregulation, potentially leading to the development or exacerbation of EBV-associated diseases.
- EBV and long COVID: Investigation of the potential role of EBV in the pathogenesis of long COVID symptoms, including fatigue, cognitive impairment, and other persistent health issues.
- EBV-associated malignancies and COVID-19: Examination of the impact of COVID-19 on the incidence, progression, and treatment of EBV-driven cancers, such as Burkitt’s lymphoma, nasopharyngeal carcinoma, and Hodgkin lymphoma.
- EBV and autoimmune diseases: Exploration of the relationship between EBV and autoimmune disorders in the context of COVID-19, including potential mechanisms and therapeutic implications.
- Novel diagnostic and therapeutic strategies: Discussion of the development of innovative approaches for the diagnosis, prevention, and treatment of EBV-related diseases in the post-COVID-19 era.
By bringing together leading experts in the field, this Special Issue seeks to advance our understanding of the complex interplay between EBV and human health, providing valuable insights for future research, prevention, and clinical management.
Dr. Xiaoming Lyu
Dr. Dengke Li
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- EBV
- reactivation and immune dysregulation
- EBV-associated malignancies
- autoimmune diseases
- diagnostic and therapeutic
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
